Duration of use, reported efficacy, and documented concerns with 349 histrelin gonadotropin-releasing hormone agonist (GnRHa) (Supprelin® LA) implants inserted in 292 individuals were examined. The median length of time that implants remained in place was 2.9 years with few failures. Very few implants were broken or brittle at the time of removal, and this status was not associated with duration of use. We conclude that in most cases, histrelin GnRHa implants can be left in place for a longer duration than the recommended 1 year. Our team routinely scheduled implant replacement at 3 years with few documented implant failures.
Get full access to this article
View all access options for this article.
References
1.
EugsterEA, ClarkeW, KletterGB, et al.Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: A multicenter trial. J Clin Endocrinol Metab, 2007; 92(5):1697–1704; doi: 10.1210/jc.2006-2479
2.
SilvermanLA, NeelyEK, KletterGB, et al.Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: A final report of a phase 3 multicenter trial. J Clin Endocrinol Metab, 2015; 100(6):2354–2363; doi: 10.1210/jc.2014-3031
3.
HirschHJ, GillisD, StrichD, et al.The histrelin implant: A novel treatment for central precocious puberty. Pediatrics, 2005; 116(6):e798–e802; doi: 10.1542/peds.2005-0538
4.
Cohen-KettenisPT, van GoozenSHM. Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. Eur Child Adolesc Psychiatry, 1998; 7(4):246–248; doi: 10.1007/s007870050073
5.
ColemanE, RadixAE, BoumanWP, et al.Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health, 2022; 23(Suppl 1):S1–S259; doi: 10.1080/26895269.2022.2100644
6.
ColemanE, BocktingW, BotzerM, et al.Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend, 2012; 13(4):165–232; doi: 10.1080/15532739.2011.700873
7.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2017; 102(11):3869–3903; doi: 10.1210/jc.2017-01658
HobsonBJ, LettE, HawkinsLA, et al.Transgender youth experiences with implantable GnRH agonists for puberty suppression. Transgend Health, 2022; 7(4):364–368; doi: 10.1089/trgh.2021.0006
10.
Pine-TwaddellE, NewfieldRS, MarinkovicM. Extended use of histrelin implant in pediatric patients. Transgend Health, 2023; 8(3):264–272; doi: 10.1089/trgh.2021.0130
11.
RayLA, EckertGJ, EugsterEA. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty. J Pediatr Endocrinol Metab, 2023; 36(3):309–312; doi: 10.1515/jpem-2022-0557
12.
NeelyEK, SilvermanLA, GeffnerME, et al.Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol, 2013; 2013(1):20; doi: 10.1186/1687-9856-2013-20
13.
LewisKA, EugsterEA. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. J Pediatr, 2013; 162(3):562–565; doi: 10.1016/j.jpeds.2012.08.038
14.
LewisKA, GoldynAK, WestKW, et al.A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr, 2013; 163(4):1214–1216; doi: 10.1016/j.jpeds.2013.05.033
15.
PappasII, CraigWY, SprattLV, et al.Efficacy of sex steroid therapy without progestin or GnRH agonist for gonadal suppression in adult transgender patients. J Clin Endocrinol Metab, 2021; 106(3):e1290–e1300; doi: 10.1210/clinem/dgaa884
